Dr. Reddy’s Laboratories Ltd. ADR [NYSE: RDY] stock went on a downward path that fall over -0.15% on Thursday, amounting to a one-week price decrease of less than -2.28%.
Over the last 12 months, RDY stock dropped by -9.62%. The one-year Dr. Reddy’s Laboratories Ltd. ADR stock forecast points to a potential upside of 14.77. The average equity rating for RDY stock is currently 2.71, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $11.06 billion, with 834.42 million shares outstanding and 833.09 million shares in the current float. Compared to the average trading volume of 1.91M shares, RDY stock reached a trading volume of 3053379 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Dr. Reddy’s Laboratories Ltd. ADR [RDY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RDY shares is $15.57 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RDY stock is a recommendation set at 2.71. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Nomura have made an estimate for Dr. Reddy’s Laboratories Ltd. ADR shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on December 19, 2024. The new note on the price target was released on January 11, 2024, representing the official price target for Dr. Reddy’s Laboratories Ltd. ADR stock.
The Average True Range (ATR) for Dr. Reddy’s Laboratories Ltd. ADR is set at 0.22, with the Price to Sales ratio for RDY stock in the period of the last 12 months amounting to 2.97. The Price to Book ratio for the last quarter was 2.98, with the Price to Cash per share for the same quarter was set at 0.84. Price to Free Cash Flow for RDY in the course of the last twelve months was 89.29 with Quick ratio for the last quarter at 1.37.
RDY Stock Performance Analysis:
Dr. Reddy’s Laboratories Ltd. ADR [RDY] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.28. With this latest performance, RDY shares gained by 1.76% in over the last four-week period, additionally sinking by -16.52% over the last 6 months – not to mention a drop of -9.62% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RDY stock in for the last two-week period is set at 48.55, with the RSI for the last a single of trading hit 49.80, and the three-weeks RSI is set at 46.56 for Dr. Reddy’s Laboratories Ltd. ADR [RDY]. The present Moving Average for the last 50 days of trading for this stock 13.55, while it was recorded at 13.49 for the last single week of trading, and 14.98 for the last 200 days.
Insight into Dr. Reddy’s Laboratories Ltd. ADR Fundamentals:
Dr. Reddy’s Laboratories Ltd. ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.37 and a Current Ratio set at 1.92.
RDY Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RDY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Dr. Reddy’s Laboratories Ltd. ADR go to -5.14%.
Dr. Reddy’s Laboratories Ltd. ADR [RDY] Institutonal Ownership Details
There are presently around $15.04%, or 15.04%% of RDY stock, in the hands of institutional investors. The top three institutional holders of RDY stocks are: JPMORGAN CHASE & CO with ownership of 0.64 million shares, which is approximately 1.9149%. ROBECO INSTITUTIONAL ASSET MANAGEMENT B.V., holding 2.07 million shares of the stock with an approximate value of $$157.65 million in RDY stocks shares; and ROBECO INSTITUTIONAL ASSET MANAGEMENT B.V., currently with $$156.61 million in RDY stock with ownership which is approximately 1.2345%.
